Conditions: Non-infectious Uveitis
Keywords: Quiescent uveitis intermediate uveitis panuveitis posterior uveitis uveitis NVS Definition: Words or phrases that best describe the protocol. Keywords help users find studies in the database. Avoid acronyms, abbreviations and trade names. Examples: Heart failure, aliskiren, heart attack, cardiovascular diseases Psoriasis, inflammatory skin disease, scaly patches
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 86
Healthy volunteers: no

Brief summary:
This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression

Detailed description:

Arms:
arm 1: AIN457 300 mg subcutaneous (s.c.) weekly for 3 weeks followed by AIN457 300 mg s.c. every 2 weeks arm 2: AIN457 300 mg s.c. at baseline for Week 2 followed by AIN457 300 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly arm 3: AIN457 150 mg s.c. and placebo s.c. at Baseline and Week 2 followed by AIN457 150 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly arm 4: Placebo s.c. every 2 weeks

Interventions: intervention 1: AIN457 intervention 2: Placebo
Intervention descriptions: intervention 1: AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake intervention 2: Matching placebo to AIN457

Protocol document: